Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
Gn-RH agonists or surgical castration are considered standard treatment for patients affected by metastatic prostate cancer. Despite greater cost, chemical castration is often considered the treatment of choice as it is psychologically better tolerated. We report our experience of one patient undergoing treatment with Gn-RH agonist who developed an early resistance to the administered drug, with serum testosterone levels within the range of normality.
Rocco
B
B
European Institute of Oncology, Milan, Italy. bernardo.rocco@ieo.it
Ferrari
M
M
Scardino
E
E
Matei
D V
DV
Verweij
F
F
Varela
R
R
De Cobelli
O
O
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017430:Prostate-Specific Antigen; D016729:Leuprolide